LifeSci Capital initiated coverage of Opus Genetics (IRD) with an Outperform rating and $8 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Opus Genetics: Favorable Risk‑Reward in OPGx-BEST1 Gene Therapy Underpins Buy Rating and $6 Price Target
- Opus Genetics: Validated AAV Platform and High-Value IRD Pipeline Underpin Buy Rating and Attractive Risk‑Reward
- Opus Genetics launches gene therapy clinical trial for retinitis pigmentosa
- Opus Genetics initiated with a Buy at BTIG
- Opus Genetics Highlights Gene Therapy Strategy at JPM Conference